Advertisement
Advertisement

AYTU

AYTU logo

Aytu BioPharma Inc

1.76
USD
+0.01
+0.57%
Jan 17, 12:25 UTC -5
Closed
...

Aytu BioPharma Inc Profile

About

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado.

Info & Links

CEO

Joshua R. Disbrow

Headquarters

7900 E. UNION AVENUE, SUITE 920
DENVER, CO 80237, UNITED STATES

Auditor

GRANT THORNTON LLP

Share holders

187

Employees

102

Aytu BioPharma Inc Statistics

Valuation Measures

Market Capitalization2

10.82M

Enterprise Value

7.27M

Enterprise Value/EBITDA(ttm)

2.41

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

0.14

Price to Book(mrq)

0.36

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

67.32%

Operating Margin(ttm)

-8.79%

Profit Margin(ttm)

-7.21%

Return on Equity(ttm)

-21.89%

Return on Invested Capital(ttm)

-20.77%

Return on Assets(ttm)

-5.37%

Income Statement

Revenue(ttm)

79.76M

Revenue Per Share(ttm)

12.97

Gross Profit(ttm)

53.53M

EBITDA(ttm)3

3.01M

Net Income Available to Common(ttm)

-6.25M

Diluted EPS(ttm)

-1.23

Share Statistics

Beta (5Y Monthly)

-1.43

52-Week Change

-26.05%

S&P 500 52-Week Change

23.90%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

6.15M

Dividend Yield

0.00%

Float4

5.98M

% Held by Insiders

2.77%

% Held by Institutions

33.49%

Balance Sheet

Total Cash(mrq)

20.11M

Total Cash Per Share(mrq)

3.27

Total Debt(mrq)

16.56M

Total Debt/Equity(mrq)

55.51%

Current Ratio(mrq)

0.99%

Quick Ratio(mrq)

0.80%

Book Value Per Share(mrq)

4.85

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.13

Free Cash Flow(ytd)

-809.00K

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement